Nerivio Wearable Migraine Therapeutic Now Eligible for Insurance Coverage through UpScript’s Telemedicine Platform
“It is our mission to make Nerivio accessible to everyone who experiences migraine episodes,” said Theranica CEO Alon Ironi.
Nerivio has shown clinical efficacy for episodic and chronic migraine, both in clinical trials and real-world evidence analyses reports Jason Sico, MD, Associate Professor of Neurology and Internal Medicine in Yale School of Medicine.
The use of the device in the treatment of adolescents is supported by a study recently published in Headache.
Nerivio Receives FDA Clearance of Expanded Indication to Cover Chronic Migraine Patients Reports Theranica
Nerivio now has clearance for use in acute treatment of migraine with or without aura in patients 18 years of age or older, without limitation to episodic migraine. The clearance is supported by results from two clinical studies with chronic migraine patients.
The article Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine, reviews a pilot study and a pivotal study conducted to determine the safety and efficacy of the Nerivio™, Theranica's smartphone-connected prescription migraine wearable device. Both studies showed positive results, demonstrating REN is as effective a treatment for acute treatment of migraine as standard pharmacological treatments, with a favorable safety profile.
FDA Grants Theranica De Novo to Market 1st Smartphone-controlled Acute Migraine-relief Wearable Device
Theranica announced that the U.S. Food and Drug Administration granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®
3/18/19: Nerivio Migra®, the company's novel remote neuromodulation device for acute treatment of migraine, is currently under review of the FDA.